You are here

Drug Safety Revisions: FDA Update

Marvin M. Goldenberg, PhD, RPh, MS
PDF version: 
The FDA has issued new labeling changes for efavirenz, rituximab, levothyroxine, zoledronic acid, infliximab, and some of the second-generation antidepressants.